Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 29;12(8):1676–1687. doi: 10.1158/1535-7163.MCT-12-1019

Figure 3. TLR4 mediates the response of BC cells to nab-PXL.

Figure 3

(A, B) Western blot analysis of NF-κB p-p50, NF-κB p50, NF-κB p-p65, NF-κB p65, p-Akt, Akt, Bcl-2, Bcl-xL and β-actin proteins in 231Cntrl, 231TLR4−, 1806Cntrl, and 1806TLR4+ cells treated with nab-PXL (10nM, 48hrs). (C, D) Cell cycle analysis by FACS of PI-stained cells treated with nab-PXL for 48hrs. Data are presented as mean percentage of cells in different stages of cell cycle ±S.D. from three experiments. (E, F) Apoptosis of 231Cntrl, 231TLR4−, 1806Cntrl, and 1806TLR4+ cells treated with nab-PXL for 48hrs determined by FACS measurement of% Annexin-and PI-positive cells. Data are presented as mean percentage of apoptotic cells ±S.D. from three experiments. Asterisks indicate P-values <0.05 vs. control as determined by Student’s unpaired t-test.